FGF23 and secondary hyperparathyroidism: Current evidence points to a fibroblast growth factor 23 (FGF23)-mediated mechanism, resulting in renal phosphate wasting, hypovitaminosis D, hypocalcemia, and secondary hyperparathyroidism [2,5,6].